{"denoms":[{"counts":[{"groupId":"BG000","value":"8"}],"units":"Participants"}],"groups":[{"description":"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin.","id":"BG000","title":"One Arm"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"62.0","upperLimit":"72.5","value":"64.5"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Relapse"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Refractory"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease status at study entry","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Absent"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Present"}]}],"description":"Symptoms B: absence of systemic symptoms; systemic symptoms defined as Night sweating, fever or Weight loss.","paramType":"COUNT_OF_PARTICIPANTS","title":"Systemic B symptoms","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"III"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"IV"}]}],"description":"Staging for lymphomas disease, ranging from I (disease located in single region) to IV (diffuse or disseminated involvement of one or more extralymphatic organs)","paramType":"COUNT_OF_PARTICIPANTS","title":"Ann Arbor Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"1"}]}],"description":"ECOG Performance status: scale ranging from 0 (person fully active) to 5 (death)","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Negative"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Positive"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Bone marrow involvement","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"4"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"5"}]}],"description":"Extranodal localization by CT scan or combined PET-CT (Magnetic Resonance Imaging if CT cannot be done).","paramType":"COUNT_OF_PARTICIPANTS","title":"Number extra-nodal sites","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"6 cy CHOEP + 1 cy DHAP + ASCT"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"6 cy CHOP+DHAP+ASCT"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"CHOEP"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"6cy CHOEP + ARA-C + ABMT"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"CHOP"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"COEP"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"CHOEP +HSCT"}]}],"description":"CHOEP: cyclophosphamide doxorubicin vincristine Etoposide Prednisone DHAP: rituximab dexamethasone cytarabine cisplatin ASCT: autologous stem cell transplant ARA-C: cytarabine CHOP: cyclophosphamide doxorubicine vincristine prednisone COEP: cyclophosphamide etoposide vincristine prednisone HSCT: haematopoietic stem cell transplantation","paramType":"COUNT_OF_PARTICIPANTS","title":"Type of the 1st Line Treatment","unitOfMeasure":"Participants"}]}